Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07746765 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

Study acronym: GusTaCon
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date pushed from Sep 30, 2026 to Oct 30, 2026 Completion pushed from Sep 30, 2029 to Oct 30, 2029 · Eligibility criteria expanded, about 8 words · Secondary endpoints: details revised at 33 of 50 entries Show 3 more changesShow less
    • Completion pushed from Sep 30, 2029 to Oct 30, 2029
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 33 of 50 entries
  2. Start date: Aug 3, 2026 to Sep 30, 2026 Completion pushed from Aug 3, 2029 to Sep 30, 2029v2 Show 1 more changeShow less
    • Completion pushed from Aug 3, 2029 to Sep 30, 2029
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.
Trial Details
NCT Number NCT07746765
Lead Sponsor Janssen Sciences Ireland UC
Conditions Crohn Disease, Colitis, Ulcerative
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov